about
Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation.Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical applicationA heparin mimetic isolated from a marine shrimp suppresses neovascularization.Platelet-derived growth factor-DD targeting arrests pathological angiogenesis by modulating glycogen synthase kinase-3beta phosphorylation.Ocular delivery of macromoleculesThe role of anti-inflammatory agents in age-related macular degeneration (AMD) treatmentAllosteric regulation of pathologic angiogenesis: potential application for angiogenesis-related blindness.Ocular distribution, spectrum of activity, and in vivo viral neutralization of a fully humanized anti-herpes simplex virus IgG Fab fragment following topical applicationAnti-tumor necrosis factor alpha for retinal diseases: current knowledge and future conceptsDrug delivery via porous silicon: a focused patent review.Blockade of Tumor Necrosis Factor-Alpha: A Role for Adalimumab in Neovascular Age-Related Macular Degeneration Refractory to Anti-Angiogenesis Therapy?Inhibition of pathological retinal neovascularization by semaphorin 3A.Endothelial heparan sulfate in angiogenesis.Adalimumab for Ocular Inflammation.Sustained Subconjunctival Delivery of Infliximab Protects the Cornea and Retina Following Alkali Burn to the Eye.Clinical review: treatment of vitreoretinal lymphoma.CD154 blockade modulates the ratio of Treg to Th1 cells and prolongs the survival of allogeneic corneal grafts in mice.Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma.Characteristics of Macular Edema in Behcet Disease after Intravitreal Bevacizumab Injection.Keratoprosthesis in autoimmune disease.Applications of aptamers in nanodelivery systems in cancer, eye and inflammatory diseases.Vitreous humor in the pathologic scope: insights from proteomic approaches.Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization.Modeling intraocular bacterial infections.Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies.Recalcitrant psoriatic uveitis and anti-tumor necrosis factor-α monoclonal antibodies: experience from a psoriasis referral center.Intravitreal injection of ranibizumab and CTGF shRNA improves retinal gene expression and microvessel ultrastructure in a rodent model of diabetesPrinciples of pharmacology in the eye.The inhibitory effect of different concentrations of KH902 eye drops on corneal neovascularization induced by alkali burn.Therapeutic approaches for corneal neovascularization.Ocular delivery of proteins and peptides: challenges and novel formulation approaches.Cytokine and chemokine tear levels in patients with uveitis.Study of aqueous cytokines in patients with different patterns of diabetic macular edema based on optical coherence tomography.Measuring the intravitreal mobility of nanomedicines with single-particle tracking microscopy.Comment on Durrani et al.'s "Adalimumab for Ocular Inflammation".Intravitreal bevacizumab injection for persistent serous retinal detachment associated with Vogt-Koyanagi-Harada disease.Intraocular Penetration of a vNAR: In Vivo and In Vitro VEGF165 Neutralization.Retinal and choroidal angiogenesis: a review of new targets.Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network
P2860
Q27693189-D013141B-5AF9-43E4-AB71-BC68E18C8787Q28082140-7B82D9E0-6606-404C-9BA8-391615652594Q33584177-F48FAB0C-D831-48E1-AA8E-C6566D79A5BEQ33832464-6B89C4CB-CBB4-4976-9E7D-E32B2D0DB17AQ34079676-1C8A75CB-A72E-4F39-AE20-446DF3FB2BD0Q34605896-40C9B4B0-12C1-402F-A5F5-2295296223F9Q35084192-E3ADDA40-BAAB-4BEA-B246-57A52A85B057Q35806468-67F3CD14-E5C9-4CF2-93D4-59FB9306E99FQ36052279-8CBFDE90-487F-4123-A202-83B5F430E6B0Q36293574-7535D58A-D503-471A-9862-C06B4A26DC09Q36766273-3B1D2B47-F443-4A12-AFE4-4C66EA83C1A6Q36964256-3F378D3C-8B4F-4316-BDA7-4DDA65BFB128Q36989520-79B4753F-27C2-40D9-9009-9C2F9F66A54BQ37276953-9D8F1A5A-6EBA-47C9-8C24-4F5762E112D1Q37583272-793E5B14-CD1F-4FEB-87CE-02BCAC622266Q37615331-1C42A87B-AFED-46E8-8E81-3F633D04D5F5Q37652140-06773D00-960B-440B-A8B6-682DEAD771D3Q37672460-0B882D3D-8156-455F-83A2-BBB446D510FCQ37684328-8495F7F9-A405-47B2-9E4D-7D78BC9C0C2CQ37775974-3EDD68AE-7383-45D8-A02C-5137671EA951Q37815481-BD5E6819-14E1-4DB2-8432-05B52AD4604BQ38293676-1ED43A9C-A2F2-4100-9869-30C908AA6FB7Q38755418-A550B3D3-73A2-449D-8D51-4ABF6D7CD931Q38827899-D92CFA06-7C68-4BFB-A1B5-8CEEA71F8842Q39110385-418FAD93-5D12-40FB-9834-0A685F9F19F8Q41564725-4BB8EDC8-1037-4D29-9A04-2DACF193BC83Q41902127-DD99C99A-15B8-4A4E-B243-AC71CA2BC8D2Q45871474-FAF1DF9B-94B2-4009-A985-6560000BA641Q47114470-D03ADDD9-E7E4-4621-9139-FCBBD5C767C1Q47143268-BF57938F-74E4-4714-941B-150770F25A1EQ47729137-55F29514-5B2F-478E-9FD1-B6ACB6FB6815Q48206476-19F32C6B-DC58-4D45-8577-BBEA321FB8F9Q48277485-39FC53B1-70F9-48A7-8C47-5ADD47359BA7Q48735724-75D2A2BB-33BD-4E5B-B31E-706DB9013BFAQ50094383-80209315-5AA2-4845-AB12-B4EEE1677B5DQ50544506-9AFCCC3C-EC6D-4D82-AAD1-8A726392AD55Q52609710-C18C72DF-9558-4692-A309-9FC452C42CF0Q53098522-DD97C464-EED8-45B3-BB0F-70CE213E2A5AQ57612721-19CD16B6-2C03-4866-84EA-BA433680F056
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapeutic monoclonal antibodies in ophthalmology.
@en
Therapeutic monoclonal antibodies in ophthalmology.
@nl
type
label
Therapeutic monoclonal antibodies in ophthalmology.
@en
Therapeutic monoclonal antibodies in ophthalmology.
@nl
prefLabel
Therapeutic monoclonal antibodies in ophthalmology.
@en
Therapeutic monoclonal antibodies in ophthalmology.
@nl
P2093
P1476
Therapeutic monoclonal antibodies in ophthalmology.
@en
P2093
Caio Regatieri
Carlos R Zanetti
Fernando M Penha
Gustavo B Melo
Marcelo M Pinheiro
Michel E Farah
P304
P356
10.1016/J.PRETEYERES.2008.11.005
P577
2008-12-10T00:00:00Z